OncoQuest Inc.

Mar 24, 2020

OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer

Mar 13, 2020

OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.

Jan 25, 2019

OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

Jun 01, 2018

Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting

May 14, 2018

Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer

Feb 12, 2018

OncoQuest to Present at BIO CEO & Investor Conference

Feb 06, 2018

OncoQuest Completes US$6 Million Private Placement

Nov 14, 2017

OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)

Nov 02, 2017

OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting

Jul 26, 2017

First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer

Jun 27, 2017

OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer